Ingrid Bandeira Moss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ingrid Bandeira Moss has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Blanca Elena Rios Gomes Bica
Rheumatology Division, Federal University of Rio de Janeiro (UFRJ), Clementino Fraga Filho University Hospital, Rio de Janeiro, Brazil
1 shared publication Carla Gottgtroy
Department of Medical Affairs, Clinical Studies, and Post-Registration Surveillance (DEAME), Bio-Manguinhos/Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil
1 shared publication- Ewerton Alves Portela dos Santos
Department of Medical Affairs, Clinical Studies, and Post-Registration Surveillance (DEAME), Bio-Manguinhos/Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil
1 shared publication - Gabriela Sadigurschi
Universidade Federal do Rio de Janeiro, Brasil
1 shared publication - Helena Tupinambá
Rheumatology Division, Internal Medicine Department, Pedro Ernesto University Hospital, State University of Rio de Janeiro (HUPE/UERJ), Rio de Janeiro, Brazil
1 shared publication - Janaina Reis Xavier
Departamento de Assuntos Médicos, Estudos Clínicos e Vigilância Pós-Registro (DEAME), Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, Brazil
1 shared publication
Latest Publications
- Open Access
- 19 August 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Understanding barriers: patient experience with immune-mediated rheumatic diseases in Brazilian public health
Background: Immune-mediated rheumatic diseases (IMRDs) encompass a wide range of rheumatological conditions that have a substantial impact on morbidity and mortality globally. Due to the diversified nature of IMRD symptoms, timely recognition of these conditions in primary care settings can be challenging. The duration between symptom onset and treatment initiation is a key factor influencing prognosis of IMRD. Therefore, this study aims to evaluate the medical journey of individuals with IMRD from symptom onset to treatment. Methods: Cross-sectional observational study based on the analysis of questionnaire responses from 1,327 patients with IMRDs at two reference centers for rheumatic disease treatment in Rio de Janeiro. Quantitative variables were compared using the Mann-Whitney or Kruskal-Wallis test, while categorical and nominal variables were analyzed using McNemar’s test. Results: The median time until the first rheumatologist consultation after symptom onset was 7 months (0,5-216 months) and the median time to obtain a definitive diagnosis of IMRD was 12 months (0,5-216 months). This period was shorter for individuals with systemic lupus erythematosus (SLE), with a median of 8 months (0.5–216 months), and longer for those with psoriatic arthritis (PsA), with a median of 33 months (2-195 months). Additionally, the median time from symptom onset to specific treatment initiation was also 12 months. It was shown that consulting two or more non-rheumatologists doctors before seeing a rheumatologist significantly delayed the IMRD diagnosis (p-value < 0.001). The diagnosis of IMRD had a negative impact on emotional well-being and occupational capacity on 85.9% ( n = 1,139) of participants’ and 68.1% ( n = 903) indicated that their work was somehow affected in a negative way. Throughout the diagnostic journey, negative feelings predominated in the period in which the diagnosis was not defined, but there was a notable shift after the confirmation of the diagnosis with an increase in positive emotions such as happiness, comfort, and well-being. Conclusions: This study provides valuable information on the challenges faced in the medical journey of patients with IMRDs, from delays in diagnosis to barriers in accessing treatment and the impact on well-being, highlighting the need for multifaceted interventions to improve the management of these complex conditions.
- 19 August 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Open AccessUnderstanding barriers: patient experience with immune-mediated rheumatic diseases in Brazilian public health
Background: Immune-mediated rheumatic diseases (IMRDs) encompass a wide range of rheumatological conditions that have a substantial impact on morbidity and mortality globally. Due to the diversified nature of IMRD symptoms, timely recognition of these conditions in primary care settings can be challenging. The duration between symptom onset and treatment initiation is a key factor influencing prognosis of IMRD. Therefore, this study aims to evaluate the medical journey of individuals with IMRD from symptom onset to treatment. Methods: Cross-sectional observational study based on the analysis of questionnaire responses from 1,327 patients with IMRDs at two reference centers for rheumatic disease treatment in Rio de Janeiro. Quantitative variables were compared using the Mann-Whitney or Kruskal-Wallis test, while categorical and nominal variables were analyzed using McNemar’s test. Results: The median time until the first rheumatologist consultation after symptom onset was 7 months (0,5-216 months) and the median time to obtain a definitive diagnosis of IMRD was 12 months (0,5-216 months). This period was shorter for individuals with systemic lupus erythematosus (SLE), with a median of 8 months (0.5–216 months), and longer for those with psoriatic arthritis (PsA), with a median of 33 months (2-195 months). Additionally, the median time from symptom onset to specific treatment initiation was also 12 months. It was shown that consulting two or more non-rheumatologists doctors before seeing a rheumatologist significantly delayed the IMRD diagnosis (p-value < 0.001). The diagnosis of IMRD had a negative impact on emotional well-being and occupational capacity on 85.9% ( n = 1,139) of participants’ and 68.1% ( n = 903) indicated that their work was somehow affected in a negative way. Throughout the diagnostic journey, negative feelings predominated in the period in which the diagnosis was not defined, but there was a notable shift after the confirmation of the diagnosis with an increase in positive emotions such as happiness, comfort, and well-being. Conclusions: This study provides valuable information on the challenges faced in the medical journey of patients with IMRDs, from delays in diagnosis to barriers in accessing treatment and the impact on well-being, highlighting the need for multifaceted interventions to improve the management of these complex conditions.